Other substances

aRBD-2-5

A biparatopic anti-RBD (SARS-CoV-2 Spike) antibody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

aRBD-2-5 is a hetero-bivalent (biparatopic) nanobody construct prepared by fusion of two anti-RBD (SARS-CoV-2) nanobodies identified in immunized alpacas. The parent nanobodies were identified using a phage display technique. The hetero-bivalent nanobody showed sub-nanomolar KD and ND50in vitro (Ma et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
Spike protein Biophysical assay In vitro Antibody 		alpacas (sera donors); in vitro binding assay; in vitro biophysical assay; Vero E6 cells; SARS-CoV-2 isolate USA-WA1/2020 4.50

The nanobody construct binds RBD with a KD of 59.2 pM (12.3 pM for an Fc fusion construct) and neutralizes SARS-CoV-2 with an ND50 of ca. 0.043 nM in vitro.

 Mar/03/2021
Export (.csv)